FY2028 EPS Estimates for Novavax Cut by Zacks Research

Key Points

• Zacks Research cut its FY2028 EPS estimate for Novavax to $0.78 from $0.92, while the consensus current full-year EPS remains negative at ($0.06).
• Novavax recently beat quarterly expectations, reporting $0.11 EPS versus an expected ($0.66) and revenue of $136.4 million, up 66.6% year-over-year.
• Analyst sentiment is mixed with a consensus "Hold" and $11.88 price target; five analysts rate the stock Buy, two Hold and three Sell, and HC Wainwright raised its target to $16.

Novavax, Inc. (NASDAQ:NVAX - Free Report) - Stock analysts at Zacks Research dropped their FY2028 earnings per share estimates for shares of Novavax in a research note issued on Wednesday, April 22nd. Zacks Research analyst Team now forecasts that the biopharmaceutical company will earn $0.78 per share for the year, down from their previous estimate of $0.92. The consensus estimate for Novavax's current full-year earnings is ($0.06) per share.

A number of other equities analysts have also weighed in on the company. Jefferies Financial Group reissued a "buy" rating on shares of Novavax in a research report on Thursday, March 12th. Wall Street Zen raised shares of Novavax from a "sell" rating to a "hold" rating in a report on Saturday, February 28th. Weiss Ratings upgraded shares of Novavax from a "sell (d+)" rating to a "hold (c-)" rating in a report on Thursday, March 12th. B. Riley Financial reiterated a "buy" rating on shares of Novavax in a research note on Thursday, April 9th. Finally, HC Wainwright increased their price target on Novavax from $11.00 to $16.00 and gave the company a "buy" rating in a report on Friday, February 27th. Five equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $11.88.

Novavax Price Performance

Novavax stock opened at $8.15 on Friday. Novavax has a one year low of $5.80 and a one year high of $11.97. The business's fifty day moving average is $9.16 and its 200 day moving average is $8.23. The stock has a market capitalization of $1.33 billion, a PE ratio of 3.38 and a beta of 2.65.

Novavax (NASDAQ:NVAX - Get Free Report) last posted its earnings results on Thursday, February 26th. The biopharmaceutical company reported $0.11 EPS for the quarter, topping analysts' consensus estimates of ($0.66) by $0.77. Novavax had a negative return on equity of 673.17% and a net margin of 39.19%.The business had revenue of $136.40 million during the quarter, compared to analyst estimates of $90.26 million. During the same quarter last year, the company earned ($0.51) EPS. The company's quarterly revenue was up 66.6% compared to the same quarter last year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Quarry LP purchased a new position in Novavax during the third quarter valued at approximately $33,000. Flagship Harbor Advisors LLC bought a new position in Novavax in the 4th quarter worth $33,000. Danske Bank A S bought a new stake in Novavax during the third quarter valued at about $64,000. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Novavax by 25.8% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,896 shares of the biopharmaceutical company's stock valued at $53,000 after acquiring an additional 1,617 shares in the last quarter. Finally, State of Wyoming bought a new position in shares of Novavax in the second quarter worth about $52,000. 53.04% of the stock is owned by hedge funds and other institutional investors.

About Novavax

Novavax, Inc is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, that specializes in the discovery, development and commercialization of next-generation vaccines to prevent serious infectious diseases. Founded in 1987, the company has built a platform based on recombinant nanoparticle technology and its proprietary Matrix-M™ adjuvant to enhance immune responses.

The company's lead product is NVX-CoV2373, a protein-based vaccine designed to elicit a robust immune response against the SARS-CoV-2 virus.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.